PGEN vs. CLLS, LUNA, BASI, GLPG, NAMS, KROS, EVO, HRMY, KURA, and EWTX
Should you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Cellectis (CLLS), Luna Innovations (LUNA), Bioanalytical Systems (BASI), Galapagos (GLPG), NewAmsterdam Pharma (NAMS), Keros Therapeutics (KROS), Evotec (EVO), Harmony Biosciences (HRMY), Kura Oncology (KURA), and Edgewise Therapeutics (EWTX).
Precigen (NASDAQ:PGEN) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations, earnings and community ranking.
Precigen currently has a consensus price target of $10.00, suggesting a potential upside of 488.24%. Cellectis has a consensus price target of $8.50, suggesting a potential upside of 230.74%. Given Precigen's higher probable upside, research analysts plainly believe Precigen is more favorable than Cellectis.
In the previous week, Precigen had 3 more articles in the media than Cellectis. MarketBeat recorded 6 mentions for Precigen and 3 mentions for Cellectis. Precigen's average media sentiment score of 0.51 beat Cellectis' score of 0.00 indicating that Precigen is being referred to more favorably in the media.
Precigen has higher earnings, but lower revenue than Cellectis. Precigen is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.
Cellectis has a net margin of -529.81% compared to Precigen's net margin of -1,781.72%. Precigen's return on equity of -65.36% beat Cellectis' return on equity.
33.5% of Precigen shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 44.9% of Precigen shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Precigen has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.09, suggesting that its stock price is 209% more volatile than the S&P 500.
Precigen received 26 more outperform votes than Cellectis when rated by MarketBeat users. However, 67.84% of users gave Cellectis an outperform vote while only 67.24% of users gave Precigen an outperform vote.
Summary
Precigen beats Cellectis on 10 of the 18 factors compared between the two stocks.
Get Precigen News Delivered to You Automatically
Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Precigen Competitors List
Related Companies and Tools
